medigraphic.com
SPANISH

Revista Médica Electrónica

ISSN 1684-1824 (Electronic)
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2016, Number 6

<< Back Next >>

Rev Méd Electrón 2016; 38 (6)

Presentation of a patient carrying a progressive supra-nuclear paralysis

Arredondo BA, Huerta RJ, Domínguez CT, Pérez ZJ
Full text How to cite this article

Language: Spanish
References: 14
Page: 887-893
PDF size: 136.64 Kb.


Key words:

neurodegeneration, supranuclear paralysis, parkinsonism.

ABSTRACT

The progressive supra-nuclear paralysis (PSP) or Steele-Richardson-Olszewsky’s syndrome is a strange, degenerative illness produced by the deterioration and gradual death of brain selected areas. We present the case of a female patient, aged 80 years, who refers postural instability, frequent falls and cognitive dysfunctions. She also presents stiffness in retrocollis in the back of the neck, fall of eyelids, left hand shaking, dysarthric and incoherent language, and shaking of both hands in coins counting. The cardiovascular examination showed 2nd increased beat, systolic murmur III/IV in mitral focus, AT 160/90 mm of Hg, edemas in both inferior members, hearth frequency of 110 beats/min., and jugular ingurgitation. The rest of the physical examination was normal. The etiologic diagnosis was progressive supranuclear paralysis and dilated cardiomyopathy. The tau protein is important in the maintenance of the neuronal morphology through microtubules formation, the different proportions and locations, causing the Richardson’s syndrome. The most common symptoms of this entity are postural instability and frequent falls, dysarthria, hypokinesia and visual alterations. Magnetic resonance and functional neuroimaging help the diagnosis.


REFERENCES

  1. 1- Richardson JC, Steele J, Olszewski J. Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. A clinical report on eight cases of "heterogeneous system degeneration". Trans Am Neurol Assoc. 1963;88:25-9.

  2. 2- Carmona-Abellán MM, Luquin MR, Lamet I, et al. Perfil neuropsicológico de la degeneración lobar frontotemporal. Anales Sis San Navarra [Internet]. 2015 Abr [citado 3 Mar 2016];38(1):79-92. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1137-66272015000100009&lng=es

  3. 3- Erro ME, Gil Alzueta M. Parálisis supranuclear progresiva. Rev Neurol [Internet]. 2012 [citado 3 Mar 2016];54(Supl 4):53-8. Disponible en: http://neurologia.com/sec/resumen.php?or=web&i=e&id=2012517

  4. 4- Boeve BF. Progressive supranuclear palsy. Parkinsonism Relat Disord. Jan 2012;18(Suppl. 1):S192-4. Citado en PubMed; PMID: 22166432.

  5. 5- León-Manríquez E, Velázquez-Osuna S, Morales-Briceño H, et al. Comparación de la calidad de vida en pacientes con parálisis supranuclear progresiva y enfermedad de Parkinson y su repercusión en el cuidador. Arch Neurocien [Internet]. 2015 [citado 3 Mar 2016]; 20(2):99-103. Disponible en: http://www.researchgate.net/profile/Amin_Cervantes-Arriaga/publication/280741052_Comparacion_de_la_calidad_de_vida_en_pacientes_con_paralisis_supranuclear_progresiva_y_enfermedad_de_Parkinson_y_su_repercusion_en_el_cuidador/links/55c4f28208aea2d9bdc394d5.pdf

  6. 6- Ling H, de Silva R, Massey LA, et al. Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant. Neuropathol Appl Neurobiol. 2014;40(2):149-63. Citado en PubMed Central; PMCID: PMC4260147.

  7. 7- Whitwell JL, Jack CR, Parisi JE, et al. Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology. Eur J Neurol [Internet]. 2013 [citado 3 Mar 2016];20(10):1417-22. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/ene.12212/full

  8. 8- Kvickström P, Eriksson B, Van Westen D, et al. Selective frontal neurodegeneration of the inferior fronto-occipital fasciculus in progressive supranuclear palsy (PSP) demonstrated by diffusion tensor tractography. BMC Neurol. 2011;11(13). Citado en PubMed Central; PMCID: PMC3041656.

  9. 9- Jecmenica-Lukic M, Petrovic IN, Pekmezovic T, et al. Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study. J Neurol [Internet]. 2014 [citado 3 Mar 2016];261(8):1575-83. Disponible en: http://link.springer.com/article/10.1007/s00415-014-7384-x

  10. 10- Armstrong RA. White matter pathology in progressive supranuclear palsy (PSP): a quantitative study of 8 cases. Clin Neuropathol [Internet]. 2013 [citado 3 Mar 2016];32(5):399-405. Disponible en: http://www.dustri.com/article_response_page.html?artId=10566&doi=10.5414/NP300608&L=0

  11. 11- Sale P, Stocchi F, Galafate D, et al. Effects of robot assisted gait training in progressive supranuclear palsy (PSP): a preliminary report. Front Hum Neurosci. 2014;8:207. Citado en PubMed Central; PMCID: PMC4029018.

  12. 12- Hutchinson M, Raff U, Chaná P, et al. Spin-lattice distribution MRI maps nigral pathology in progressive supranuclear palsy (PSP) during life: a pilot study. PLoS One. 2014;9(1):e85194. Citado en PubMed Central; PMCID: PMC3904838.

  13. 13- Joshi AC, Riley DE, Mustari MJ, et al. Selective defects of visual tracking in progressive supranuclear palsy (PSP): implications for mechanisms of motion vision. Vision Res. 2010;50(8):761-71. Citado en PubMed Central; PMCID: PMC2846391.

  14. 14- Vázquez Sánchez F, Redondo-Robles L, Galiana Ivars A, et al. Neuroimagen funcional en el estudio de los parkinsonismos: PET y SPECT. Rev Neurol [Internet]. 2012 [citado 3 Mar 2016];54(Supl 4): S33-S9. Disponible en: http://neurologia.com/sec/resumen.php?or=web&i=e&id=2012514




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Méd Electrón. 2016;38